VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+4.29%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$891M
AUM Growth
+$891M
(+688%)
Cap. Flow
+$760M
Cap. Flow
% of AUM
85.31%
Top 10 Holdings %
Top 10 Hldgs %
57.95%
Holding
371
New
107
Increased
50
Reduced
125
Closed
30
Top Buys
| 1 |
EQM
EQM Midstream Partners, LP
EQM
|
$78.1M |
| 2 |
ETP
Energy Transfer Partners, L.P.
ETP
|
$77.3M |
| 3 |
MPLX
MPLX
|
$72.7M |
| 4 |
Marathon Petroleum
MPC
|
$61.2M |
| 5 |
ENLK
EnLink Midstream Partners, LP
ENLK
|
$43.2M |
Top Sells
| 1 |
Incyte
INCY
|
$9.28M |
| 2 |
ACGN
Aceragen, Inc. Common Stock
ACGN
|
$3.92M |
| 3 |
Vanguard Utilities ETF
VPU
|
$1.69M |
| 4 |
Vanguard Energy ETF
VDE
|
$1.3M |
| 5 |
iShares MSCI India ETF
INDA
|
$1.24M |
Sector Composition
| 1 | Energy | 74% |
| 2 | Healthcare | 7.58% |
| 3 | Utilities | 1.27% |
| 4 | Financials | 0.09% |
| 5 | Technology | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Omeros
OMER
$283M
| $970K | 0.1% | 39,755 +2,679 | +7% | +$65.4K |
|
52
Neurocrine Biosciences
NBIX
$13.8B
| $962K | 0.1% | 7,823 +527 | +7% | +$64.8K |
|
|
SGEN
53
DELISTED
Seagen Inc. Common Stock
SGEN
| $922K | 0.1% | 11,953 +805 | +7% | +$62.1K |
|
54
Biogen
BIIB
$19.4B
| $905K | 0.09% | 2,561 +173 | +7% | +$61.1K |
|
|
MNTA
55
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $895K | 0.09% | 34,033 +2,293 | +7% | +$60.3K |
|
56
Gilead Sciences
GILD
$140B
| $886K | 0.09% | 11,485 +741 | +7% | +$57.2K |
|
|
CELG
57
DELISTED
Celgene Corp
CELG
| $880K | 0.09% | 9,832 +673 | +7% | +$60.2K |
|
58
United Therapeutics
UTHR
$13.8B
| $877K | 0.09% | 6,856 +462 | +7% | +$59.1K |
|
59
Ionis Pharmaceuticals
IONS
$6.8B
| $853K | 0.09% | 16,532 +1,114 | +7% | +$57.5K |
|
60
Nektar Therapeutics
NKTR
$568M
| $846K | 0.09% | 13,877 +935 | +7% | +$57K |
|
61
BioMarin Pharmaceuticals
BMRN
$11.2B
| $844K | 0.09% | 8,700 +586 | +7% | +$56.8K |
|
62
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
$17.8B
| $838K | 0.09% | +9,698 | New | +$838K |
|
63
Public Service Enterprise Group
PEG
$41.1B
| $818K | 0.08% | +15,489 | New | +$818K |
|
64
Travere Therapeutics
TVTX
$1.56B
| $806K | 0.08% | 28,067 +1,891 | +7% | +$54.3K |
|
65
Ironwood Pharmaceuticals
IRWD
$214M
| $778K | 0.08% | 42,130 +2,839 | +7% | +$52.4K |
|
66
Arrowhead Research
ARWR
$3.05B
| $758K | 0.08% | 39,546 -29,041 | -42% | -$557K |
|
67
Rigel Pharmaceuticals
RIGL
$697M
| $751K | 0.08% | 234,017 +16,032 | +7% | +$51.4K |
|
|
XLRN
68
DELISTED
Acceleron Pharma Inc.
XLRN
| $750K | 0.08% | 13,104 -9,365 | -42% | -$536K |
|
69
Halozyme
HALO
$8.56B
| $749K | 0.08% | 41,199 +2,776 | +7% | +$50.5K |
|
|
70
Incyte
INCY
$16.5B
| $742K | 0.08% | 742 -9,282 | -93% | -$9.28M |
|
|
71
Vanguard Utilities ETF
VPU
$7.27B
| $735K | 0.08% | 6,238 -14,307 | -70% | -$1.69M |
|
|
TSRO
72
DELISTED
TESARO, Inc.
TSRO
| $725K | 0.07% | 18,590 +1,273 | +7% | +$49.6K |
|
73
Ultragenyx Pharmaceutical
RARE
$2.89B
| $721K | 0.07% | 9,441 +647 | +7% | +$49.4K |
|
74
Exelixis
EXEL
$10.1B
| $706K | 0.07% | 39,851 +2,719 | +7% | +$48.2K |
|
75
Viking Therapeutics
VKTX
$3.04B
| $696K | 0.07% | 39,960 -29,345 | -42% | -$511K |
|